Risk of Paradoxical Eczema in Patients Receiving Biologics for Psoriasis
JAMA Dermatology, 2023.
Ali Al-Janabi; Oras A. Alabas; Zenas Z. N. Yiu; Amy C. Foulkes; Steve Eyre; Adnan R. Khan; Nick J. Reynolds; Catherine H. Smith; Christopher E. M. Griffiths; Richard B. Warren; the BADBIR Study Group.
Read publication: JAMA Dermatology
Related
Uptake of tumour necrosis factor-alpha inhibitor biosimilars for psoriasis: a drug utilization study...
The association of age at psoriasis onset and HLA-C*06:02 with biologic survival in patients with mo...
Risk of Major Cardiovascular Events in Patients With Psoriasis Receiving Biologic Therapies: A Prosp...
0 Comments